Additionally, the combination of IDO1 inhibitors together with immune checkpoint inhibitors, such as anti-programmed cell death 1 (PD1) and anti-programmed cell death ligand 1 (PD-L1), have opened new avenues towards increasing the efficacy of immuno-oncology in cancer treatment [78,79,80]. Here, PDCD1 is linked to cancer.